| An inhibitor of oxidative phosphorylation exploits cancer vulnerability JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T McAfoos, ... Nature medicine, 1, 2018 | 712 | 2018 |
| Androgen deprivation causes epithelial–mesenchymal transition in the prostate: implications for androgen-deprivation therapy Y Sun, BE Wang, KG Leong, P Yue, L Li, S Jhunjhunwala, D Chen, K Seo, ... Cancer research 72 (2), 527-536, 2012 | 402 | 2012 |
| IGF-II is regulated by microRNA-125b in skeletal myogenesis Y Ge, Y Sun, J Chen The Journal of cell biology 192 (1), 69-81, 2011 | 276 | 2011 |
| Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis Y Sun, Y Ge, J Drnevich, Y Zhao, M Band, J Chen The Journal of cell biology 189 (7), 1157-1169, 2010 | 234 | 2010 |
| Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state GV Echeverria, Z Ge, S Seth, X Zhang, S Jeter-Jones, X Zhou, S Cai, Y Tu, ... Science translational medicine 11 (488), eaav0936, 2019 | 233 | 2019 |
| Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer YL Deribe, Y Sun, C Terranova, F Khan, J Martinez-Ledesma, J Gay, ... Nature medicine, 1, 2018 | 229 | 2018 |
| Phospholipase D1 is an effector of Rheb in the mTOR pathway Y Sun, Y Fang, MS Yoon, C Zhang, M Roccio, FJ Zwartkruis, M Armstrong, ... Proceedings of the National Academy of Sciences 105 (24), 8286-8291, 2008 | 227 | 2008 |
| Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma L Zhang, Y Yao, S Zhang, Y Liu, H Guo, M Ahmed, T Bell, H Zhang, G Han, ... Science translational medicine 11 (491), eaau1167, 2019 | 202 | 2019 |
| Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells Y Sun, A Daemen, G Hatzivassiliou, D Arnott, C Wilson, G Zhuang, M Gao, ... Cancer & metabolism 2 (1), 20, 2014 | 141 | 2014 |
| Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect MS Yoon, Y Sun, E Arauz, Y Jiang, J Chen Journal of Biological Chemistry, jbc. M111. 262816, 2011 | 141 | 2011 |
| mTOR signaling: PLD takes center stage Y Sun, J Chen Cell Cycle 7 (20), 3118-3123, 2008 | 101 | 2008 |
| Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib Y Sun, BA Meyers, B Czako, P Leonard, F Mseeh, AL Harris, Q Wu, ... Cancer Research, 2020 | 56 | 2020 |
| Mechanistic target of rapamycin (mTOR) controls homeostasis of adipogenesis MS Yoon, C Zhang, Y Sun, CJ Schoenherr, J Chen Journal of lipid research, jlr. M037705, 2013 | 51 | 2013 |
| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... Nature metabolism, 1-14, 2020 | 47 | 2020 |
| Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation Y Sun, M Bandi, T Lofton, M Smith, CA Bristow, A Carugo, N Rogers, ... Cell Reports 26 (2), 469-482. e5, 2019 | 47 | 2019 |
| Mechanism-specific pharmacodynamics of a novel complex-I inhibitor quantified by imaging reversal of consumptive hypoxia with [18F] FAZA PET in vivo ST Gammon, F Pisaneschi, ML Bandi, MG Smith, Y Sun, Y Rao, F Muller, ... Cells 8 (12), 1487, 2019 | 22 | 2019 |
| Electrochemical investigation of the chloride effect on hemoglobin Y Sun, X Liu, C Fan, W Zhang, G Li Bioelectrochemistry 64 (1), 23-27, 2004 | 20 | 2004 |
| An electrochemical investigation of ligand-binding abilities of film-entrapped myoglobin W Zhang, C Fan, Y Sun, G Li Biochimica et Biophysica Acta (BBA)-General Subjects 1623 (1), 29-32, 2003 | 20 | 2003 |
| Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent … B Czako, Y Sun, T McAfoos, JB Cross, PG Leonard, JP Burke, CL Carroll, ... Journal of Medicinal Chemistry 64 (20), 15141-15169, 2021 | 17 | 2021 |
| NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. A Drilon, JC Horan, A Tangpeerachaikul, B Besse, SI Ou, SM Gadgeel, ... Cancer Discovery, CD-22, 2022 | 14 | 2022 |
